- Daré Bioscience’s ROIC is an impressive 483.52%, significantly outperforming its competitors in the biopharmaceutical sector.
- The company’s ROIC to WACC ratio stands at 55.94, indicating efficient use of capital to create value.
- Comparatively, peers like vTv Therapeutics Inc. (VTVT), Achieve Life Sciences, Inc. (ACHV), Cocrystal Pharma, Inc. (COCP), ENDRA Life Sciences Inc. (NDRA), and Xenetic Biosciences, Inc. (XBIO) exhibit negative ROIC to WACC ratios, highlighting potential inefficiencies in their investment strategies.
Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company focused on developing innovative products for women’s health. The company aims to address unmet needs in areas such as contraception, fertility, and sexual health. In a competitive landscape, Daré Bioscience distinguishes itself through its strong financial metrics, particularly its Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC).
Daré Bioscience’s ROIC stands at an impressive 483.52%, significantly higher than its WACC of 8.64%. This results in a ROIC to WACC ratio of 55.94, indicating that the company is generating substantial returns on its investments relative to the cost of capital. This metric suggests that Daré Bioscience is efficiently using its capital to create value, a positive sign for potential investors.
In comparison, vTv Therapeutics Inc. (VTVT) has a negative ROIC of -84.31% and a WACC of 6.44%, resulting in a ROIC to WACC ratio of -13.09. This negative ratio indicates that vTv Therapeutics is not generating sufficient returns to cover its cost of capital, highlighting potential inefficiencies in its investment strategies.
Similarly, Achieve Life Sciences, Inc. (ACHV) and Cocrystal Pharma, Inc. (COCP) also exhibit negative ROIC to WACC ratios of -8.85 and -14.53, respectively. These figures suggest that both companies face challenges in generating returns that exceed their capital costs, which could impact their long-term profitability and growth prospects.
ENDRA Life Sciences Inc. (NDRA) and Xenetic Biosciences, Inc. (XBIO) also struggle with negative ROIC to WACC ratios of -78.95 and -4.97, respectively. Despite Xenetic Biosciences having the highest ratio among its peers, it remains negative, indicating that the company is still not achieving profitability relative to its cost of capital. This comparison underscores Daré Bioscience’s strong position in terms of capital efficiency and potential for value creation.
